JP2010509331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509331A5 JP2010509331A5 JP2009536282A JP2009536282A JP2010509331A5 JP 2010509331 A5 JP2010509331 A5 JP 2010509331A5 JP 2009536282 A JP2009536282 A JP 2009536282A JP 2009536282 A JP2009536282 A JP 2009536282A JP 2010509331 A5 JP2010509331 A5 JP 2010509331A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective amount
- taxane
- vegf antibody
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940123237 Taxane Drugs 0.000 claims description 47
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 45
- 239000002105 nanoparticle Substances 0.000 claims description 34
- 206010027476 Metastases Diseases 0.000 claims description 22
- 230000009401 metastasis Effects 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 102000014914 Carrier Proteins Human genes 0.000 claims description 13
- 108010078791 Carrier Proteins Proteins 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/594,417 | 2006-11-06 | ||
| US11/594,417 US20070166388A1 (en) | 2005-02-18 | 2006-11-06 | Combinations and modes of administration of therapeutic agents and combination therapy |
| PCT/US2007/023446 WO2008057562A1 (en) | 2006-11-06 | 2007-11-06 | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013230872A Division JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509331A JP2010509331A (ja) | 2010-03-25 |
| JP2010509331A5 true JP2010509331A5 (enExample) | 2011-12-15 |
| JP5931323B2 JP5931323B2 (ja) | 2016-06-08 |
Family
ID=39111840
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536282A Active JP5931323B2 (ja) | 2006-11-06 | 2007-11-06 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2013230872A Withdrawn JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2015208557A Pending JP2016014073A (ja) | 2006-11-06 | 2015-10-23 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013230872A Withdrawn JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2015208557A Pending JP2016014073A (ja) | 2006-11-06 | 2015-10-23 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20070166388A1 (enExample) |
| EP (3) | EP2481405B1 (enExample) |
| JP (3) | JP5931323B2 (enExample) |
| KR (4) | KR20090087906A (enExample) |
| CN (2) | CN104940929A (enExample) |
| AU (1) | AU2007317859B2 (enExample) |
| BR (1) | BRPI0718528A2 (enExample) |
| CA (1) | CA2668607A1 (enExample) |
| CY (2) | CY1115271T1 (enExample) |
| DK (2) | DK2097078T3 (enExample) |
| ES (2) | ES2576289T3 (enExample) |
| HU (1) | HUE028472T2 (enExample) |
| IL (2) | IL198576A (enExample) |
| MX (1) | MX2009004803A (enExample) |
| NO (1) | NO343908B1 (enExample) |
| NZ (1) | NZ576856A (enExample) |
| PL (2) | PL2097078T3 (enExample) |
| PT (2) | PT2097078E (enExample) |
| RU (2) | RU2009121568A (enExample) |
| SI (2) | SI2097078T1 (enExample) |
| WO (1) | WO2008057562A1 (enExample) |
| ZA (1) | ZA200903132B (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20070116761A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| ES2435944T3 (es) * | 1997-06-27 | 2013-12-26 | Abraxis Bioscience, Llc | Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| WO2006089290A1 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience Inc.. | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8034765B2 (en) * | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| US8440625B2 (en) * | 2006-06-26 | 2013-05-14 | University Of British Columbia | Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| EP2089055A4 (en) * | 2006-11-01 | 2011-02-02 | George Mason Intellectual Prop | METHOD FOR THE DETECTION AND CONTROL OF CANCER |
| PT2117520T (pt) | 2006-12-14 | 2018-12-04 | Abraxis Bioscience Llc | Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane |
| LT2481402T (lt) * | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| JP2010530872A (ja) * | 2007-06-22 | 2010-09-16 | サイドース・エルエルシー | Ｔｗｅｅｎ８０を含まないドセタキセル可溶化製剤 |
| ITMI20080284A1 (it) * | 2008-02-22 | 2009-08-23 | Indena Spa | Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono |
| CA2721153C (en) * | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| WO2010003057A2 (en) | 2008-07-03 | 2010-01-07 | Mayo Foundation For Medical Education And Research | Treating cancer |
| EP2153821A1 (en) * | 2008-08-06 | 2010-02-17 | BioAlliance Pharma | Oral formulations of camptothecin derivatives |
| RU2555326C2 (ru) * | 2009-01-16 | 2015-07-10 | Риджел Фармасьютикалз, Инк. | ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА |
| BRPI1008955A2 (pt) | 2009-03-13 | 2015-09-01 | Abraxis Bioscience Llc | Terapia de combinação com derivados de tiocolchicina. |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| EP2451459B1 (en) * | 2009-07-07 | 2017-11-22 | Normoxys, Inc. | Method of reducing multi-drug resistance using inositol tripyrophosphate |
| US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
| TWI619509B (zh) | 2010-02-23 | 2018-04-01 | 建南德克公司 | 治療先前未經治療之ⅲ期或ⅳ期卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、太平洋紫杉醇與抗-vegf抗體之組合 |
| CN104784121A (zh) * | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| NZ602385A (en) * | 2010-03-29 | 2014-08-29 | Abraxis Bioscience Llc | Methods of treating cancer |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| MY166014A (en) * | 2010-06-07 | 2018-05-21 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
| US20120121510A1 (en) * | 2010-11-11 | 2012-05-17 | Brem Rachel F | Localized therapy following breast cancer surgery |
| US20130323265A1 (en) * | 2010-11-15 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| HRP20200793T1 (hr) | 2011-05-09 | 2020-10-16 | Mayo Foundation For Medical Education And Research | Liječenje raka |
| TW201700103A (zh) | 2011-11-01 | 2017-01-01 | 西建公司 | 利用胞嘧啶核苷類似物之口服配方治療癌症的方法 |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| PT2790675T (pt) | 2011-12-14 | 2019-09-23 | Abraxis Bioscience Llc | Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas |
| SI2825558T1 (sl) | 2012-03-13 | 2019-08-30 | F. Hoffmann-La Roche Ag | Kombinirana terapija za zdravljenje raka jajčnikov |
| CA2917407C (en) | 2012-10-01 | 2023-03-14 | Mayo Foundation For Medical Education And Research | Complexes containing albumin-containing nanoparticles and antibodies to treat cancer |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| NZ630239A (en) * | 2013-02-11 | 2017-08-25 | Abraxis Bioscience Llc | Methods of treating melanoma |
| ES2804323T3 (es) | 2013-03-12 | 2021-02-05 | Abraxis Bioscience Llc | Procedimientos de tratamiento de cáncer de pulmón |
| CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| US10842969B2 (en) | 2013-10-25 | 2020-11-24 | Mercator Medsystems, Inc. | Systems and methods of treating malacia by local delivery of hydrogel to augment tissue |
| WO2015134543A1 (en) * | 2014-03-05 | 2015-09-11 | Sorrento Therapeutics, Inc. | Pharmacokinetically equivalent nanoparticle compositions |
| EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
| CA2950926A1 (en) | 2014-06-13 | 2015-12-17 | Mayo Foundation For Medical Education And Research | Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas |
| JP6600651B2 (ja) | 2014-06-16 | 2019-10-30 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 骨髄腫の治療 |
| US20150359810A1 (en) | 2014-06-17 | 2015-12-17 | Celgene Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| WO2015018380A2 (en) * | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Therapeutic nanoparticles and the preparation methods thereof |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| ES2763318T3 (es) * | 2014-10-06 | 2020-05-28 | Mayo Found Medical Education & Res | Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| EP3313401B1 (en) | 2015-06-29 | 2021-10-06 | Abraxis BioScience, LLC | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| WO2017031368A1 (en) * | 2015-08-18 | 2017-02-23 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| WO2017176265A1 (en) * | 2016-04-06 | 2017-10-12 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| CN105288639A (zh) * | 2015-11-23 | 2016-02-03 | 中国药科大学 | 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用 |
| EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| EP3432926A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS |
| CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| RU2019105550A (ru) * | 2016-08-05 | 2020-09-07 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования |
| WO2018038253A1 (ja) * | 2016-08-26 | 2018-03-01 | 哲治 奥野 | 微小ナノ化薬剤およびその利用 |
| EP3506950A1 (en) | 2016-09-01 | 2019-07-10 | Mayo Foundation for Medical Education and Research | Methods and compositions for targeting t-cell cancers |
| JP7525999B2 (ja) | 2016-09-01 | 2024-07-31 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 |
| CN109843924A (zh) | 2016-09-06 | 2019-06-04 | 梅约医学教育与研究基金会 | 治疗表达pd-l1的癌症的方法 |
| RU2756892C2 (ru) | 2016-09-06 | 2021-10-06 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| CN106310291A (zh) * | 2016-09-14 | 2017-01-11 | 东南大学 | 主动靶向抗肿瘤纳米药物及其制备方法和应用 |
| PL3532059T3 (pl) | 2016-10-27 | 2022-05-09 | Celgene Quanticel Research, Inc. | Terapia skojarzona z zastosowaniem inhibitora białka bet |
| EP3532077A4 (en) * | 2016-10-28 | 2020-06-10 | Nant Holdings IP, LLC | Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death |
| RU2020118594A (ru) | 2017-11-06 | 2021-12-09 | Рапт Терапьютикс, Инк. | Противораковые агенты |
| WO2019104042A1 (en) * | 2017-11-21 | 2019-05-31 | University Of Iowa Research Foundation | Synthetically lethal nanoparticles for treatment of cancers |
| CN111683657A (zh) * | 2017-12-19 | 2020-09-18 | 阿布拉科斯生物科学有限公司 | 利用纳米颗粒mTOR抑制剂联合疗法治疗结肠癌的方法 |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
| AU2020393842A1 (en) | 2019-11-25 | 2022-06-16 | The Regents Of The University Of California | Long-acting VEGF inhibitors for intraocular neovascularization |
| KR102263606B1 (ko) | 2020-02-11 | 2021-06-10 | 충북대학교 산학협력단 | 파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도 |
| WO2026090323A1 (en) | 2024-10-23 | 2026-04-30 | Incyte Corporation | Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor and its use in the treatment of cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5470571A (en) | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| IL98528A0 (en) | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
| SK281143B6 (sk) | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| WO1995019171A1 (en) | 1994-01-14 | 1995-07-20 | Cell Therapeutics, Inc. | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
| IL132240A0 (en) | 1997-04-07 | 2001-03-19 | Genentech Inc | Anti-vegf antibodies |
| CN1125651C (zh) | 1998-04-16 | 2003-10-29 | 欧维塔有限公司 | 新颖的、含有存在于大高良姜中的芳族化合物与萜类化合物的协同组合物 |
| CA2369740A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
| ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| US20040143004A1 (en) | 2002-02-26 | 2004-07-22 | Joseph Fargnoli | Metronomic dosing of taxanes |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| NZ621449A (en) * | 2003-05-30 | 2015-07-31 | Genentech Inc | Treatment with anti-vegf antibodies |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US20080085902A1 (en) * | 2003-09-23 | 2008-04-10 | Guido Bold | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent |
| WO2006001911A2 (en) | 2004-05-06 | 2006-01-05 | Genentech, Inc. | Crystal structure of the hepatocyte growth factor beta chain and methods of use |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| EP1753455A2 (en) | 2004-06-04 | 2007-02-21 | Genentech, Inc. | Method for treating multiple sclerosis |
| SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| US8772269B2 (en) * | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| US20080161251A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| WO2006089290A1 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience Inc.. | Combinations and modes of administration of therapeutic agents and combination therapy |
| WO2006090928A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物の血管新生阻害物質との新規併用 |
| BRPI0615265A8 (pt) * | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| US8034765B2 (en) * | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
-
2006
- 2006-11-06 US US11/594,417 patent/US20070166388A1/en not_active Abandoned
-
2007
- 2007-11-06 KR KR1020097011640A patent/KR20090087906A/ko not_active Ceased
- 2007-11-06 PT PT78399763T patent/PT2097078E/pt unknown
- 2007-11-06 CN CN201510264733.0A patent/CN104940929A/zh active Pending
- 2007-11-06 AU AU2007317859A patent/AU2007317859B2/en active Active
- 2007-11-06 JP JP2009536282A patent/JP5931323B2/ja active Active
- 2007-11-06 KR KR1020157014446A patent/KR20150065957A/ko not_active Ceased
- 2007-11-06 WO PCT/US2007/023446 patent/WO2008057562A1/en not_active Ceased
- 2007-11-06 ZA ZA200903132A patent/ZA200903132B/xx unknown
- 2007-11-06 HU HUE12154995A patent/HUE028472T2/en unknown
- 2007-11-06 SI SI200731475T patent/SI2097078T1/sl unknown
- 2007-11-06 ES ES12154995.0T patent/ES2576289T3/es active Active
- 2007-11-06 CA CA002668607A patent/CA2668607A1/en not_active Abandoned
- 2007-11-06 SI SI200731795A patent/SI2481405T1/sl unknown
- 2007-11-06 MX MX2009004803A patent/MX2009004803A/es active IP Right Grant
- 2007-11-06 PL PL07839976T patent/PL2097078T3/pl unknown
- 2007-11-06 ES ES07839976.3T patent/ES2469716T3/es active Active
- 2007-11-06 RU RU2009121568/15A patent/RU2009121568A/ru unknown
- 2007-11-06 EP EP12154995.0A patent/EP2481405B1/en active Active
- 2007-11-06 EP EP16161396.3A patent/EP3108885A1/en not_active Withdrawn
- 2007-11-06 DK DK07839976.3T patent/DK2097078T3/da active
- 2007-11-06 DK DK12154995.0T patent/DK2481405T3/en active
- 2007-11-06 BR BRPI0718528-6A patent/BRPI0718528A2/pt not_active Application Discontinuation
- 2007-11-06 KR KR1020177002657A patent/KR101857142B1/ko active Active
- 2007-11-06 PL PL12154995.0T patent/PL2481405T3/pl unknown
- 2007-11-06 NZ NZ576856A patent/NZ576856A/en not_active Application Discontinuation
- 2007-11-06 PT PT121549950T patent/PT2481405E/pt unknown
- 2007-11-06 CN CNA2007800490545A patent/CN101573108A/zh active Pending
- 2007-11-06 KR KR1020187002044A patent/KR20180012339A/ko not_active Withdrawn
- 2007-11-06 EP EP07839976.3A patent/EP2097078B1/en active Active
-
2009
- 2009-05-05 IL IL198576A patent/IL198576A/en active IP Right Grant
- 2009-06-05 NO NO20092179A patent/NO343908B1/no unknown
-
2013
- 2013-11-05 RU RU2013149282A patent/RU2673805C2/ru active
- 2013-11-07 JP JP2013230872A patent/JP2014043454A/ja not_active Withdrawn
-
2014
- 2014-06-26 CY CY20141100462T patent/CY1115271T1/el unknown
-
2015
- 2015-10-23 JP JP2015208557A patent/JP2016014073A/ja active Pending
-
2016
- 2016-03-02 IL IL244390A patent/IL244390A/en active IP Right Grant
- 2016-06-17 CY CY20161100552T patent/CY1117725T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009121568A (ru) | Комбинации и способы введения терапевтических агентов и комбинированная терапия | |
| Agnello et al. | Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors | |
| JP2010529025A5 (enExample) | ||
| JP2013503174A5 (enExample) | ||
| Socinski et al. | Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer | |
| RU2021128415A (ru) | Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения | |
| JP2016506908A5 (enExample) | ||
| JP2012520323A5 (enExample) | ||
| JP2016513097A5 (enExample) | ||
| JP2013523656A5 (enExample) | ||
| JP2013527233A5 (enExample) | ||
| JP2017025090A5 (enExample) | ||
| JP2016513075A5 (enExample) | ||
| JP2014531456A5 (enExample) | ||
| RU2012157805A (ru) | Способы лечения рака мочевого пузыря | |
| US12391944B2 (en) | Magnetic inorganic iron-based nanoparticles | |
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| JP2012158602A5 (enExample) | ||
| JP2010523696A5 (enExample) | ||
| JP2015517529A5 (enExample) | ||
| JP2016512506A5 (enExample) | ||
| JP2017514800A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| JP2019529520A5 (enExample) | ||
| EP2699233A1 (en) | A method for the treatment of a solid tumour |